Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
作者： Robert Pirker , Felix JF Herth , Keith M Kerr , Martin Filipits , Miquel Taron
DOI: 10.1097/JTO.0B013E3181F1C8DE
关键词:
摘要: … Recommendations for high-quality … cells, but this is rarely achieved in routine. For DNA sequencing, the percentage of tumor cells should ideally be at least 50% although with good …
jto.org
elsevier.com
sci-hub.se 参考文章(44)
Assessing EGFR mutations. The New England Journal of Medicine. ,vol. 354, pp. 526- ,(2006) , 10.1056/NEJMC052564
Osamu Matsubara, Yuichi Ishikawa, Kentaro Inamura, Hironori Ninomiya, Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features Archives of Pathology & Laboratory Medicine. ,vol. 134, pp. 66- 72 ,(2010) , 10.1043/2008-0586-RAR1.1
Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman, Daniel A. Haber, Epidermal growth factor receptor mutations in lung cancer Nature Reviews Cancer. ,vol. 7, pp. 169- 181 ,(2007) , 10.1038/NRC2088
Junichi Soh, Shinichi Toyooka, Keisuke Aoe, Hiroaki Asano, Syuji Ichihara, Hideki Katayama, Akio Hiraki, Katsuyuki Kiura, Motoi Aoe, Yoshifumi Sano, Kazuro Sugi, Nobuyoshi Shimizu, Hiroshi Date, Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. International Journal of Cancer. ,vol. 119, pp. 2353- 2358 ,(2006) , 10.1002/IJC.22190
Marie Brevet, Maria Arcila, Marc Ladanyi, Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR The Journal of Molecular Diagnostics. ,vol. 12, pp. 169- 176 ,(2010) , 10.2353/JMOLDX.2010.090140
William Pao, Vincent A Miller, Katerina A Politi, Gregory J Riely, Romel Somwar, Maureen F Zakowski, Mark G Kris, Harold Varmus, Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain PLoS Medicine. ,vol. 2, pp. e73- ,(2005) , 10.1371/JOURNAL.PMED.0020073
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos, EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib The New England Journal of Medicine. ,vol. 352, pp. 786- 792 ,(2005) , 10.1056/NEJMOA044238
H Asahina, , K Yamazaki, I Kinoshita, N Sukoh, M Harada, H Yokouchi, T Ishida, S Ogura, T Kojima, Y Okamoto, Y Fujita, H Dosaka–Akita, H Isobe, M Nishimura, A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. British Journal of Cancer. ,vol. 95, pp. 998- 1004 ,(2006) , 10.1038/SJ.BJC.6603393
David R. Gandara, Primo N. Lara, Philip Mack, Giorgio Scagliotti, Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. Clinical Lung Cancer. ,vol. 10, pp. 148- 150 ,(2009) , 10.3816/CLC.2009.N.020
K Tamura, I Okamoto, T Kashii, S Negoro, T Hirashima, S Kudoh, Y Ichinose, N Ebi, K Shibata, T Nishimura, N Katakami, T Sawa, E Shimizu, J Fukuoka, T Satoh, M Fukuoka, Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) British Journal of Cancer. ,vol. 98, pp. 907- 914 ,(2008) , 10.1038/SJ.BJC.6604249